A Look At uniQure (QURE) Valuation After FDA Setback And Legal Investigations

Simply Wall St.02-04

uniQure (NasdaqGS:QURE) is back in focus after disclosing that the FDA views current AMT-130 gene therapy data as insufficient for a Biologics License Application, clouding timelines and drawing legal...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608807834?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-04 01:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608807834","market":"us","top_or_hot":-1,"title":"A Look At uniQure (QURE) Valuation After FDA Setback And Legal Investigations","media":"Simply Wall St.","content":"<div>\n<p>uniQure (NasdaqGS:QURE) is back in focus after disclosing that the FDA views current AMT-130 gene therapy data as insufficient for a Biologics License Application, clouding timelines and drawing legal...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/a-look-at-uniqure-qure-valuation-after-fda-setback-and-legal\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At uniQure (QURE) Valuation After FDA Setback And Legal Investigations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At uniQure (QURE) Valuation After FDA Setback And Legal Investigations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-04 01:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/a-look-at-uniqure-qure-valuation-after-fda-setback-and-legal><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>uniQure (NasdaqGS:QURE) is back in focus after disclosing that the FDA views current AMT-130 gene therapy data as insufficient for a Biologics License Application, clouding timelines and drawing legal...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/a-look-at-uniqure-qure-valuation-after-fda-setback-and-legal\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QURE","symbol_name":"uniQure N.V.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/a-look-at-uniqure-qure-valuation-after-fda-setback-and-legal","article_id":"2608807834","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/a-look-at-uniqure-qure-valuation-after-fda-setback-and-legal","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608807834","pubTimestamp":1770138994,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"uniQure (NasdaqGS:QURE) is back in focus after disclosing that the FDA views current AMT-130 gene therapy data as insufficient for a Biologics License Application, clouding timelines and drawing legal and analyst scrutiny.\nSee our latest analysis for uniQure.\nThe FDA setback has come after a volatile period, with a 56.83% 1 year total shareholder return contrasting with an 18.86% 3 month share price decline and a smaller 5.60% year to date share price gain. This suggests that momentum has...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"QURE":"uniQure N.V.","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4139":"生物科技"},"translate_title":"FDA挫折和法律调查后uniQure(QURE)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QURE":1.5},"content_text":"uniQure (NasdaqGS:QURE) is back in focus after disclosing that the FDA views current AMT-130 gene therapy data as insufficient for a Biologics License Application, clouding timelines and drawing legal and analyst scrutiny. See our latest analysis for uniQure. The FDA setback has come after a volatile period, with a 56.83% 1 year total shareholder return contrasting with an 18.86% 3 month share price decline and a smaller 5.60% year to date share price gain. This suggests that momentum has cooled recently. If you are looking beyond a single gene therapy name, this could be a good moment to broaden your search using healthcare stocks as another source of ideas in the healthcare space. With shares still up 56.83% over 1 year yet trading at a very large discount to the average analyst price target, investors are left with a simple question: is uniQure mispriced today or is the market already factoring in future growth? AdvertisementMost Popular Narrative: 55.3% Undervalued At a last close of $24.70 versus a narrative fair value of $55.27, this widely followed view sees a substantial gap between price and potential.  The analysts have a consensus price target of $35.514 for uniQure based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $69.56, and the most bearish reporting a price target of just $13.41.  Read the complete narrative. This narrative explores what kind of revenue ramp, margin shift and long-term earnings multiple could justify that gap to fair value. The full narrative lays those assumptions out in detail, including how fast the top line is modeled to grow and what profitability level would need to follow for $55.27 to be supported by the model. For readers who want to see how those moving parts fit together, the numbers are presented step by step. Result: Fair Value of $55.27 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges heavily on AMT-130 clearing current FDA hurdles and on uniQure managing manufacturing changes without major cost or supply disruptions. Find out about the key risks to this uniQure narrative. Another View: Multiples Paint a Tougher Picture While the narrative fair value of $55.27 points to a large upside, the simple book value lens is less generous. QURE trades on a P/B of 6.7x versus 2.6x for the wider US Biotechs group and 15.2x for peer averages, which raises a basic question: is the premium to the sector or the discount to peers the more important signal for you? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:QURE P/B Ratio as at Feb 2026 Build Your Own uniQure Narrative If you interpret the data differently, or prefer to test your own assumptions, you can create a new uniQure view in just a few minutes with Do it your way. A great starting point for your uniQure research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision. Looking for more investment ideas? If uniQure has your attention, do not stop there. Broaden your watchlist now so you do not miss other opportunities shaping the market.  Spot potential bargains early by scanning these 872 undervalued stocks based on cash flows that currently trade below what their cash flows might justify. Tap into early stage growth stories through these 3533 penny stocks with strong financials that pair smaller market caps with sturdier financial profiles. Ride the AI healthcare trend by focusing on these 111 healthcare AI stocks at the intersection of data science and medical breakthroughs.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if uniQure might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608807834","isCrawlerRequest":true}